CliffBio
small molecule

EMBLAVEO

AVIBACTAM SODIUM; AZTREONAM

Loss of exclusivityFebruary 2033FDA regulatory exclusivity expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameEMBLAVEO
Active ingredientAVIBACTAM SODIUM; AZTREONAM
StrengthEQ 0.5GM BASE/VIAL;1.5GM/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2025
Marketing statusRX

Listed patents

PatentExpiresType
9695122June 2032substance, product
8969566June 2032substance
9284314June 2032substance
8471025August 2031substance
8835455October 2030product
7612087November 2026product
7112592January 2026substance, product

Regulatory exclusivity

CodeExpires
GAINFebruary 2033
NPFebruary 2028

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.